Blastomyces Dermatitidis QNT AG
U BLUAGSO
Aid in the diagnosis of blastomycosis
Monitor the response to therapy and to determine when treatment can be modified or stopped
Monitor Blastomyces antigen levels to help determine relapses of disease
Ship to arrive Monday through Saturday using a next day delivery service.
Samples may be shipped on dry ice, frozen ice packs or ambient.
Specimens received cold or room temperature >14 days old
Non-pipettable specimens, tissue, biopsy, sputum, bronchial brush, tracheal aspirate, FNA, bone marrow, aspirate or stool
Samples in transport media, fixative or isolator tubes
It is possible that specimens positive for Candida tropicalis, Coccidioides immitis, Coccidioides posadasii, Histoplasma capsulatum, Histoplasma duboisii, Paracoccidioides brasiliensis, Talaromyces marneffei and Aspergillus nidulans may cross-react with the Blastomyces Antigen EIA and test positive.
A variety of interfering substances, as follows, were investigated for each specimen type and none affected the Blastomyces Antigen EIA sensitivity or specificity.
The MVista® Blastomyces Antigen Quantitative EIA can detect and quantify the amount of Blastomyces antigen in patient samples.
During validation testing, the sensitivity was found to be 95.00% and specificity 100% with an assay cutoff of 0.31 ng/mL.
Positive samples may require confirmation which could extend TAT.
Negative results do not exclude blastomycosis. Testing of both urine and serum offers the highest sensitivity. Failure of the antigen to rise does not exclude relapse.
None Detected: <0.31 ng/mLPositive: ≥0.31 ng/mL – 20.00 ng/mLPositive Above the Limit of QuantificationsResults greater than 20.00 ng/mL fall outside the linear range of the assay. These results are positive, but not accurately quantifiable.
Results should be correlated with clinical presentation and history